Participated · Seed · Aug 2026

BioScout builds an AI-powered early warning platform that captures and analyzes airborne crop pathogens before visible field damage occurs. Its automated hardware uses an active wind vane to trap airborne particles onto an internal adhesive tape, which is then positioned beneath a high-resolution robotic microscope for imaging. Proprietary machine learning models analyze the physical morphology of over 40 distinct agricultural threats, including Alternaria and Downy Mildew. The company currently operates a global automated sensor network of about 250 units and plans to scale to 1,000 active deployments by 2029. BioScout intends to expand commercially across Europe and enter the Brazilian soybean market. The company is led by founder and CEO Dr. Lewis Collins and recently raised A$6.75m (US$4.8m) in Seed funding.

Participated · Seed · Jul 2026

Juno Bio offers an at-home vaginal microbiome test that screens for bacteria, fungi and some sexually transmitted infections, and provides an analysis of microbes linked to conditions like bacterial vaginosis and yeast infections. Tests are available in 46 states and are priced at $149 for a single test or $99 for a test every three months, with patients able to book a free follow-up call with a company coach to review results and next steps. The company cites data indicating 67.5% of its customers had been incorrectly diagnosed before using the test and only 13% had been successfully treated. Juno Bio is establishing a CLIA-certified sequencing lab in Oakland to bring testing in-house, improve turnaround and support future research and clinical standardization. Founder and chief science officer Leighton Turner and CEO Hana Janebdar have framed the next phase as scaling clinical infrastructure, expanding access to actionable care and advancing understanding of the vaginal microbiome.

Participated · Series A · Mar 2026

PlasmaLeap designs, manufactures and sells modular plasma reactors that synthesize ammonia and nitric acid from air, water and renewable power, eliminating the fossil-fuel inputs and heavy transport normally required for nitrogen fertiliser production. Spun out of the University of Sydney, the company targets on-farm or local hub installations that cut growers’ input costs, lower supply-chain risk and slash CO₂ emissions from fertiliser manufacturing, transport and field losses—an impact area that accounts for roughly 2.5 % of global industrial emissions. Its platform is also being engineered to make e-fuels, synthetic hydrocarbons and other industrial chemicals, opening pathways to decarbonise hard-to-abate sectors like energy and transport. PlasmaLeap is currently progressing first-of-a-kind fertiliser hubs in New South Wales and Tasmania and expanding field trials to validate commercial performance. Management expects the solution to generate high-quality carbon credits and improve national food security by shielding farmers from global price shocks. Financially, the company has just secured almost A$30 million (US$20 million) in Series A capital to fund these deployments and further R&D, adding to earlier grants such as support from the Gates Foundation.

Led · Series A · Dec 2025

Ferronova is an Adelaide-based medical technology company developing a super-paramagnetic iron oxide nanoparticle tracer system designed to improve image-guided cancer surgery. The nanoparticles bind to lymph-node cells, allowing surgeons to identify tissue that may harbour metastasised cancer and thereby reduce post-operative recurrence. The company is running a 60-patient, two-year clinical trial on stomach and oesophageal cancers at leading Australian centres, having enrolled 54 patients with completion expected in early 2026. Management plans to extend research to the United States over the next two years as it moves toward regulatory approval and commercial launch. Roughly 1.8 million people are diagnosed with stomach and oesophageal cancers annually, underscoring the market need the firm targets. Ferronova has raised a cumulative $17.5 million in Series A funding, giving it capital to complete trials and pursue commercialisation. Its investor base includes Uniseed/UniSuper, South Australian Venture Capital Fund, Artesian Venture Partners, Renew Pharmaceuticals (UltraGreen.ai), several universities, and health-focused funds. The company’s mission is to enhance surgical precision and improve survival rates in complex, early-stage cancers.

Led · Seed · Nov 2025

Founded in 2022 by Cambridge-trained researchers Ben Woodington and Elise Jenkins, San Francisco–based Coherence Neuro decodes the body’s electrical patterns to understand and correct disease states. Its flagship device, SOMA-1, continually records neural activity and delivers precise stimulation, creating a bi-directional, closed-loop therapy that aims to nudge tumorous tissue back toward healthy function. Each deployed device feeds data into what the company calls the world’s largest disease-focused dataset, allowing the system to learn and improve with every patient. Coherence frames cancer as a system-level error rather than an external invader, seeking to replace aggressive treatments like surgery and chemotherapy with continuous, gentler neuromodulation. The company plans to begin first-in-human trials next year, using its newly secured capital to validate safety and efficacy. To date, it has raised a $10 million seed round to fund these efforts and further develop its data-driven platform.